Novartis Ag (NVS-N) Quote

GlobeNewswire – Mon Dec 21, 7:04AM CST announces the release of the report “Biosimilar Lymphocyte Modulator Global Market Report 2020-30: COVID-19 Growth and Change” –

21 billion in 2020 at a compound annual growth rate (CAGR) of -5.57%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $1.67 billion in 2023 at a CAGR of 11.1%.

The biosimilar lymphocyte modulator market consists of sales of immune regulating lymphocyte modulators by entities (organizations, sole traders and partnerships) that manufacture lymphocyte modulator biosimilars. Lymphocyte modulators are intended as an aid in the treatment for cancer and autoimmune diseases, and for regulating carotene intake in humans with a weak immune system. Only goods and services traded between entities or sold to end consumers are included.

In July 2020, Cytocom, Inc., a US-based immunotherapy generating company, announced the acquisition with ImQuest Life Sciences, Inc. for an undisclosed sum. The deal is expected to support Cytocom’s vision of strategic growth and strengthen internal drug development programs with new assets and secured revenue-generating operations, scientific resources, and tools and capacity. ImQuest Life Sciences is a US-based company with leading drug discovery and development. The company was founded in 2004.

The biosimilar lymphocyte modulator market covered in the report is segmented by drug into campath-1h; natalizumab biosimilar; efalizumab – a1089-anti-CD11a biosimilar; anti-cd38 daratumumab biosimilar; anti-cs1 elotuzumab biosimilar and by disease into arthritis; diabetes; multiple myeloma; enterocolitis; multiple sclerosis; psoriasis; others.

1 2 3 4